DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hwz37s/lebers) has announced the addition of the "Leber's Hereditary Optic ...
Researchers from Landeskrankenhaus Salzburg (SALK) - Universitätsklinikum der PMU have identified a novel loss-of-function variant in the NDUFA7 gene in a patient with Leber’s hereditary optic ...
A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
GS010 reported to be safe and well-tolerated A clinically meaningful improvement of +11 ETDRS letters reported in the 37 subjects in both eyes Unexpected improvement in the untreated eye suggests a ...
Pratteln, Switzerland, June 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces positive topline results from itslong-term Phase 4 LEROS study with Raxone® (idebenone) in the treatment of ...
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 PARMA, ...
GenSight’s gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight improvement over five years. France-based GenSight ...
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback